News
SVRA
4.740
-1.04%
-0.050
FYBR, BCRX and SABR are among after hour movers
On the Move FYBR, BCRX and SABR are among after hour movers. Travere Therapeutics (TVTX) and Nextracker (NXT) gain. Avidity Biosciences (RNA) and Netflix (NFLX) lose ground.
Seeking Alpha · 17h ago
Savara Price Target Maintained With a $8.00/Share by JMP Securities
Dow Jones · 20h ago
JMP Securities Reiterates Market Outperform on Savara, Maintains $8 Price Target
Benzinga · 21h ago
3 Best Stocks to Buy Now, 4/18/2024, According to Top Analysts
TipRanks · 1d ago
Analysts Offer Insights on Healthcare Companies: Savara (SVRA), Johnson & Johnson (JNJ) and Lantheus (LNTH)
Savara, Johnson & Johnson and Lantheus are 3 of the top 3 Healthcare stocks recommended by analysts. Savara has an analyst consensus of Strong Buy, with a price target of $8.80. 3 analysts have reiterated a Buy rating on Savara.
TipRanks · 1d ago
Weekly Report: what happened at SVRA last week (0408-0412)?
Weekly Report · 4d ago
SAVARA INC - ON APRIL 10, RICKY SUN NOTIFIED BOARD OF DIRECTORS OF HIS INTENTION NOT TO STAND FOR REELECTION TO BOARD
Reuters · 6d ago
SAVARA INC - ON APRIL 10, BAIN CAPITAL LIFE SCIENCES NOTIFIED CO IT WAS PERMANENTLY WAIVING DESIGNATION RIGHT
Reuters · 6d ago
Savara Inc. Experiences Board Changes and Governance Shifts
TipRanks · 6d ago
Savara Up Nearly 11%, on Pace for Largest Percent Increase Since June 2023 -- Data Talk
Savara, Inc. (SVRA) is currently at $5.25, up $0.51 or 10.76%. Up five of the past five days, up 11.7% month-to-date. Up 200% from its all-time closing high of $9953.12 on Jan. 2, 2001.
Dow Jones · 04/11 18:52
Optimistic Buy Rating for Savara Based on Molgramostim’s Market Potential and Study Outcomes
TipRanks · 04/09 12:05
Savara To Present New Data On Autoimmune Pulmonary Alveolar Proteinosis At The American Thoracic Society International Conference 2024
Savara's Partner, Trillium Health LLC, to Present Data on the Laboratory Blood Test for Diagnosing aPAP Company to Host Industry Theater on Pulmonary Alveolar Proteinosis (PAP) with two world-renowned experts at the American Thoracic Society 2024 International Conference.
Benzinga · 04/08 12:28
Weekly Report: what happened at SVRA last week (0401-0405)?
Weekly Report · 04/08 09:12
Savara Insiders Sold US$632k Of Shares Suggesting Hesitancy
Savara Inc. Insiders have sold more shares than they bought in the last year. The Chairman & CEO of Savara, Matthew Pauls, made the biggest insider sale in the past year. Savara owns 2.4% of the company. In the last 12 months, Savara insiders purchased 106.50k shares for US$278k. But the insider sale of shares at a lower price is not a major concern for shareholders. You should look at Savara's insider Transactions over the Last Year.
Simply Wall St · 04/05 11:08
Weekly Report: what happened at SVRA last week (0325-0329)?
Weekly Report · 04/01 09:12
Weekly Report: what happened at SVRA last week (0318-0322)?
Weekly Report · 03/25 09:12
Savara Announces New Employment Inducement Grant
Savara Inc. Is a clinical stage biopharmaceutical company focused on rare respiratory diseases. The inducement awards to two new employees were granted on March 21, 2024. The awards consist of options to purchase an aggregate of 125,000 shares of the Company's common stock.
Barchart · 03/22 15:05
Weekly Report: what happened at SVRA last week (0311-0315)?
Weekly Report · 03/18 09:12
HC Wainwright & Co. Reiterates Buy on Savara, Maintains $6 Price Target
Benzinga · 03/11 10:49
Buy Rating Affirmed: Anticipating IMPALA-2 Trial Success and aPAP Treatment Breakthrough with Molgramostim
TipRanks · 03/11 10:26
More
Webull provides a variety of real-time SVRA stock news. You can receive the latest news about Savara Inc through multiple platforms. This information may help you make smarter investment decisions.
About SVRA
Savara Inc. is a clinical-stage biopharmaceutical company, which is focused on rare respiratory diseases. The Company’s lead program, molgramostim nebulizer solution (molgramostim), is an inhaled biologic, specifically an inhaled granulocyte-macrophage colony-stimulating factor (GM-CSF) in Phase III development for autoimmune pulmonary alveolar proteinosis (aPAP). Molgramostim is an inhaled formulation of recombinant human GM-CSF and is being developed for the treatment of aPAP. Molgramostim nebulizer solution is administered once daily by inhalation via a high efficiency nebulizer, the eFlow Nebulizer System (PARI Pharma GmbH). Pulmonary alveolar proteinosis (PAP) is a rare lung disease characterized by the accumulation of surfactant in the alveoli (or air sacs) of the lungs. The Company is engaged in the advancement of the molgramostim aPAP program and the Phase III IMPALA-2 clinical trial and outsourcing capital-intensive operations.